Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2007 1
2011 1
2012 1
2013 1
2014 2
2015 1
2016 1
2017 1
2018 3
2019 6
2020 7
2021 3
2022 3
2023 1
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Smart sustainable biorefineries for lignocellulosic biomass.
Culaba AB, Mayol AP, San Juan JLG, Vinoya CL, Concepcion RS 2nd, Bandala AA, Vicerra RRP, Ubando AT, Chen WH, Chang JS. Culaba AB, et al. Among authors: concepcion rs 2nd. Bioresour Technol. 2022 Jan;344(Pt B):126215. doi: 10.1016/j.biortech.2021.126215. Epub 2021 Oct 30. Bioresour Technol. 2022. PMID: 34728355 Review.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
Shore ND, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, Tammela TLJ, Morris D, Aragon-Ching JB, Concepcion RS, Emmenegger U, Fleshner N, Grabbert M, Lietuvietis V, Mahammedi H, Cruz FM, Paula A, Pieczonka C, Rannikko A, Richardet M, Silveira G, Kuss I, Le Berre MA, Verholen F, Sarapohja T, Smith MR, Fizazi K. Shore ND, et al. Among authors: concepcion rs. Oncologist. 2024 Jul 5;29(7):581-588. doi: 10.1093/oncolo/oyae019. Oncologist. 2024. PMID: 38394384 Free PMC article. Clinical Trial.
Infusion therapy and implantables for the urologist.
Rothschild J, Thompson IM 3rd, Concepcion RS, Shore ND. Rothschild J, et al. Among authors: concepcion rs. Urol Clin North Am. 2013 Nov;40(4):591-8. doi: 10.1016/j.ucl.2013.07.014. Urol Clin North Am. 2013. PMID: 24182978 Review.
Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Shore ND, Polikarpov DM, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt DA, Chan DW, Deng N, Siddireddy JS, Lu Y, Campbell DH, Walsh BJ. Shore ND, et al. Among authors: concepcion rs. Urol Oncol. 2023 Nov;41(11):454.e9-454.e16. doi: 10.1016/j.urolonc.2023.08.005. Epub 2023 Sep 19. Urol Oncol. 2023. PMID: 37734979
Obesity, body composition, and prostate cancer.
Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA. Fowke JH, et al. Among authors: concepcion rs. BMC Cancer. 2012 Jan 18;12:23. doi: 10.1186/1471-2407-12-23. BMC Cancer. 2012. PMID: 22257467 Free PMC article.
31 results